Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3064
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines.

    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
AC Immune
Active Biotech
Adaptimmune
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alfa Wassermann
Alfacell
Allos Therapeutics
AlphaVax
Ambit Biosciences
Amgen
Antisense Pharma
Anza Therapeutics
Apogee Biotechnology
Apotex
Apricus Biosciences
Ardea Biosciences
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biolex
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
Borean Pharma
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Research Technology
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CritiTech
CSL
Curaxis
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DeveloGen
Dr Reddy’s
Dynavax Technologies
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
Exelixis
Favrille
FibroGen
Forma Therapeutics
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GenPat77
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Hayashibara
Heat Biologics
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MBiotec
Meda
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
Noxxon
Nycomed Pharma
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Protgen
Protherics
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
SBIO
Scancell
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shionogi
Shire
SuperGen
SuppreMol
Synageva BioPharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Tau Therapeutics
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
TopoTarget
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Virionics
ViroMed
XBiotech
Xencor
Xerion
Yakult Honsha
YM BioSciences
Zenotech
Zensun
Zenyaku Kogyo
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
ADXS11-001
AE-37
AEG-35156
aflibercept
AGS-003
AGS-1C4D4
alemtuzumab
amrubicin hydrochloride
ANZ-207
apricoxib
ARC-100
ARQ-197
astuprotimut-r
Auto TAG vaccine
AVX-701
bardoxolone methyl
belagenpumatucel-L
belinostat
bevacizumab
bexarotene
bortezomib
bosutinib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
brivudine
BV-NSCLC-001
Cabozantinib
capecitabine
catumaxomab
CB-10-01
CDX-1307
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
conatumumab
CPI-613
CreaVax-PC
CRLX-101
CV-9103
CV-9201
CVac
dalotuzumab
dasatinib
DCVax-prostate
denileukin diftitox
docetaxel
doxorubicin
E-75
E-7820
elliptinium acetate
emepepimut-S
eniluracil
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
galiximab
ganitumab
gefitinib
GI-4000
GSK-1120212
GSK-2130579A
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
HS-110
ibritumomab tiuxetan
icotinib hydrochloride
ICT-107
imatinib mesilate
imMucin
IMO-2055
IMP-321
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
ipilimumab
irinotecan
irinotecan hydrochloride
ISA-P53-01
JX-594
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
LipoVIL12
masitinib
MDX-1379
MetXia
MGN-1601
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
MVA-BN Her-2 vaccine
nadroparin
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
OncoVAX
Onyvax-105
OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pixantrone
plitidepsin
poly-ICLC
polyclonal antibody stimulator
pralatrexate
PROSTVAC
PSMA ADC
PX-12
razoxane
Reditux
Reximmune-C
Rexin-G
rhIFN-alpha
rindopepimut
rintatolimod
rituximab
romidepsin
RX-0201
S-488410
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sobuzoxane
sorafenib tosylate
ß-lapachone
sunitinib malate
Survivac
talminogene laherparepvec
tegafur + uracil
temsirolimus
teniposide
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TroVax
TS-1
tucotuzumab celmoleukin
varlitinib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
WX-671
Z-360
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines.
    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Learn More


Triple Analysis: Apoptosis, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More


Triple Analysis: Breast Cancer, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More